Partnerships
Our allies in realizing the potential of neurogenetic medicine
Capsid Licenses
PROVIDE:
- Validation (third-party buy-in, potential program use)
- Near-term funding (upfront and option exercise payments)
- Long-term funding
(milestones and royalties) - Multiple ‘shots on goal’ to prove human translation
![Partner_Logo_White_Alexion](https://www.voyagertherapeutics.com/wp-content/uploads/2023/12/Partner_Logo_White_Alexion.png)
![Partner_Logo_White_Novartis](https://www.voyagertherapeutics.com/wp-content/uploads/2023/12/Partner_Logo_White_Novartis.png)
Program Partnerships
PROVIDE:
- Significant long-term potential value (profit share or milestones and royalties)
- Cost savings (program funding)
- Validation (investment into program)
- Near-term funding (upfront, early development milestone payments)
![Partner_Logo_White_Neurocrine](https://www.voyagertherapeutics.com/wp-content/uploads/2023/12/Partner_Logo_White_Neurocrine.png)
![Partner_Logo_White_Novartis](https://www.voyagertherapeutics.com/wp-content/uploads/2023/12/Partner_Logo_White_Novartis.png)
Additional Structures
PROVIDE:
- Opportunities to combine TRACER capsids and receptor technology with cutting-edge payloads and biologics, placing Voyager at forefront of neurogenetic medicine
- Various deal structures with range of participation being explored
![Partner_Logo_White_Sangamo](https://www.voyagertherapeutics.com/wp-content/uploads/2023/12/Partner_Logo_White_Sangamo.png)